Parabilis Medicines Inc. (PBLS)
NASDAQ: PBLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PBLS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.44B
- EPS (TTM)
- -$3.62
- Dividend yield
- None
- 52-week range
- 22.66 – 42.49
- Day range
- 26.50 – 28.52
- Volume / Avg
- 1.25M / 975.55K
- Beta
- —
- Shares outstanding
- 123.68M
52-week range
PBLS stock today
Shares of Parabilis Medicines (PBLS) finished lower on Nov 20 at $27.44, a drop of 0.67% or $0.185 per share, versus the S&P 500's 3.70% decline. Shares are 35.4% below their 52-week high of $42.49, set on Sep 18, 2026 and 21.1% above the 52-week low of $22.66, in the middle of the past year's range. Parabilis Medicines has posted a net loss over the last twelve months (EPS of -$3.62), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Parabilis Medicines
Company profileParabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Mathai Mammen M.D., Ph.D.
- Headquarters
- Cambridge, MA
- Employees
- 145
- IPO year
- 2026
- Website
- parabilismed.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$41.00+49.42%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.36 vs $-0.40
- Surprise
- +10.00%
PBLS news
All PBLS news- Parabilis Medicines, Inc. Loss At -$44.491 Mln In Q3NasdaqPBLS, BF.A
- Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorsGlobeNewswire
- Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026GlobeNewswire
- Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous PolyposisGlobeNewswire
- Nasdaq Listings Delivers Record-Breaking First HalfNasdaqNDAQ, SPCX, PBLS, CBRS
Parabilis Medicines peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs PBLS |
| ELVNEnliven Therapeutics Inc. | 46.53 | +0.26% | $3.42B | vs PBLS |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs PBLS |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs PBLS |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs PBLS |
| XENEXenon Pharmaceuticals Inc. | 37.04 | -1.38% | $3.64B | vs PBLS |
| OGNOrganon & Co. | 13.89 | -0.14% | $3.65B | vs PBLS |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs PBLS |
Indexes, lists and sector
Parabilis Medicines stock FAQ
What is Parabilis Medicines's stock price today?
PBLS last traded at $27.44 as of Nov 20, 4:00 PM EST, down 0.67% on the day. Prices are delayed at least 15 minutes.
Who is Parabilis Medicines's CEO?
Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines Inc., which has about 145 employees.
What is the PBLS 52-week high?
The 52-week high for PBLS is $42.49 and the 52-week low is $22.66. The stock is currently 35.4% below its high.